All In MedTech

FDA Clearance Tracker · P940035-S007

ALERE NMP22 URINE COLLECTION KIT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 20, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 20, 2012

Approved

Time to decision

177 days

Received Jul 27, 2011. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P940035-S007
Device name
ALERE NMP22 URINE COLLECTION KIT
Applicant location
Scarborough, ME
Received
Jul 27, 2011
Decided
Jan 20, 2012
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P940035

Device type

Device class
Class III

Every decision under product code NAH

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE NMP22 TEST KIT AND NMP22 URINE COLLECTION KIT UNDER ALERE SCARBOROUGH, INCS BRAND NAME. THE DEVICES, AS MODIFIED, WILL BE MARKETED UNDER: TRADE NAME ALERE NMP22 TEST WITH THE FOLLOWING INTENDED USE: ALERE NMP22 TEST IS AN ENZYME IMMUNOASSAY (EIA) FOR THE IN VITRO QUANTITATIVE DETERMINATION OF THE NUCLEAR MITOTIC APPARATUS PROTEIN (NUMA) IN STABILIZED VOIDED URINE. THE ALERE NMP22 TEST KIT IS INDICATED AS AN AID 1) IN THE DIAGNOSIS OF PERSONS WITH SYMPTOMS OR RISK FACTORS FOR TRANSITIONAL CELL CANCER (TCC) OF THE BLADDER (CUT-OFF >= 7.5 U/ML) IN CONJUNCTION WITH, AND NOT IN LIEU OF, CURRENT STANDARD DIAGNOSTIC PROCEDURES, AND 2) IN MANAGEMENT OF PATIENTS OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER, AFTER SURGICAL TREATMENT TO IDENTIFY THOSE PATIENTS WITH OCCULT OR RAPIDLY RECURRING TCC (CUT-OFF > 10 U/ML). TRADE NAME ALERE NMP22 URINE COLLECTION KIT, WITH THE FOLLOWING INTENDED USE: THE ALERE NMP22 URINE COLLECTION KIT IS INTENDED FOR THE COLLECTION, STABILIZATION, AND TRANSPORT OF HUMAN URINE WHICH WILL BE TESTED USING THE ALERE NMP22 TEST KIT.

Source documents

Other decisions for Abbott Diagnostics Scarborough, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.